0000000000054711

AUTHOR

Stefano Gonnelli

showing 6 related works from this author

The burden of previous fractures in hip fracture patients. The Break Study

2011

A positive history of fractures in older patients with hip fracture is common. We determined the risk factors associated with a positive history of fractures and the profile of care in hip fracture patients. In the Break Study, we enrolled 1249 women aged ≥60 years, seeking care for a hip fracture. Baseline information included age, body mass index, lifestyle (smoking habit, alcohol consumption), patient's history of fracture after the age of 50 years, family history of fragility fracture and health status (presence of comorbidity, use of specific drugs, pre-fracture walking ability, type of fracture, time to surgery, type of surgery, osteoporosis treatment). In the multivariable model age,…

Multiple fractureAgingPediatricsmedicine.medical_specialtyMultivariate analysisCross-sectional studyOsteoporosisPsychological interventionHip fractureBody Mass IndexRisk Factorship fractures; care; osteoporosismedicineHumanscareFamily historyAgedAged 80 and overHip fractureProfile of carebusiness.industrySettore MED/34 - Medicina Fisica E RiabilitativaMiddle Agedmedicine.diseaseosteoporosisComorbidityCross-Sectional StudiesHip fracture Break studyhip fracturesMultivariate AnalysisPhysical therapyFemaleGeriatrics and GerontologybusinessDelivery of Health CareBody mass indexAging Clinical and Experimental Research
researchProduct

Prescription of anti-osteoporosis medications after hospitalization for hip fracture: a multicentre Italian survey.

2017

Purpose: Literature data indicate that the proportion of patients with recent hip fracture who receive a prescription for anti-osteoporotic drugs is low and does not seem to increase over time. This study aimed to obtain data on the prescription for anti-osteoporotic drugs in Italian patients discharged after a recent hip fracture and to assess which variables could have influenced the decision for prescribing osteoporosis medication. Methods: A total of four Italian centres located in four different geographical areas (Siena, Verona, Naples and Palermo) participated in this retrospective study. In each centre, experienced clinicians gathered the data of up to 200 consecutive patients disch…

Malemedicine.medical_specialtyPediatricsHip fracture; Anti-osteoporotic drugs; Comorbidities; Ca/vitamin D supplementsAgingAnti-osteoporotic drugs; Ca/vitamin D supplements; Comorbidities; Hip fractureAnti-osteoporotic drugOsteoporosisAlternative medicine030209 endocrinology & metabolismComorbiditiesHip fracture03 medical and health sciences0302 clinical medicineSex FactorsSurveys and QuestionnairesmedicineHumans030212 general & internal medicineMedical prescriptionPractice Patterns Physicians'AgedRetrospective StudiesAged 80 and overHip fractureBone Density Conservation AgentsGeriatrics gerontologybusiness.industryHip FracturesSettore MED/34 - Medicina Fisica E RiabilitativaRetrospective cohort studyMean ageMiddle Agedmedicine.diseaseCa/vitamin D supplementsHospitalizationAnti-osteoporotic drugsItalyAnti osteoporosisPhysical therapyAnti-osteoporotic drugs; Ca/vitamin D supplements; Comorbidities; Hip fracture; Aging; Geriatrics and GerontologyOsteoporosisFemaleCa/vitamin D supplementComorbiditieGeriatrics and GerontologybusinessOsteoporotic FracturesAging clinical and experimental research
researchProduct

Erratum to: The burden of previuos fractures in hip fracture patients. The Break Study

2011

Agingmedicine.medical_specialtyHip fracturebusiness.industryGeriatrics gerontologyPhysical therapyMedicineGeriatrics and Gerontologybusinessmedicine.diseaseAging Clinical and Experimental Research
researchProduct

Multifactorial Assessment of Risk of Falling in 753 Post-Menopausal Women: A Multicenter Cross-Sectional Study by the Italian Group for the Study of …

2020

Giovanni Iolascon,1 Alessandro de Sire,1– 3 Dario Calafiore,1,4 Maria Grazia Benedetti,5 Carlo Cisari,2,6 Giulia Letizia Mauro,7 Silvia Migliaccio,8 Ranuccio Nuti,9 Giuseppina Resmini,10 Stefano Gonnelli,9 Antimo Moretti1 1Department of Medical and Surgical Specialties and Dentistry, University of Campania “Luigi Vanvitelli”, Naples, Italy; 2Physical and Rehabilitative Medicine, Department of Health Sciences, University of Eastern Piedmont “A. Avogadro”, Novara, Italy; 3Rehabilitation Unit, “Mons L. Novarese” Hospital, Vercelli, Moncrivello, Italy; 4Section of Neuromotor Rehabilitation, Department of Neuroscience, ASST Ca…

walking speed.medicine.medical_specialtyCross-sectional studymedicine.medical_treatmentOsteoporosiswalking speedboneaccidental falls osteoporosis walking speed fractures bone rehabilitationBone remodelingrehabilitationFractures Bone03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineVitamin D and neurologyHumansMedicineosteoporosi030212 general & internal medicineVitamin DAgedOriginal ResearchAged 80 and overRehabilitationaccidental fallbusiness.industryRC952-954.6General Medicinefracturesmedicine.diseaseosteoporosisPostmenopausePreferred walking speedCross-Sectional StudiesItalyGeriatricsfractureClinical Interventions in AgingCohortrehabilitation.Population studyFemaleaccidental fallsGeriatrics and Gerontologybusiness030217 neurology & neurosurgeryClinical Interventions in Aging
researchProduct

Retrospective evaluation of persistence in osteoporosis therapy with oral bisphosphonates in Italy: the TOBI study

2019

The patients’ persistence with osteoporosis treatments is low. This retrospective, multicenter survey showed that almost 30% of osteoporotic patients discontinued the treatment within the first 6 months and that those taking drinkable bisphosphonates were less likely to interrupt the therapy; instead, the use of generic bisphosphonates was associated to a more precocious interruption. Purpose: Low persistence with osteoporosis medications is associated with higher fracture risk. This study aimed to assess the persistence to treatment with oral bisphosphonates among Italian osteoporotic patients under treatment for at least 6 months and to evaluate whether the different oral formulations of …

MaleAgingmedicine.medical_specialtyGeneric drugmedicine.medical_treatmentOsteoporosisDrinkable bisphosphonates; Generic drug; Oral bisphosphonates; Osteoporosis; PersistenceAdministration OralPersistence (computer science)Medication AdherencePersistence03 medical and health sciencesFractures Bone0302 clinical medicineInternal medicineGeneric drugmedicineHumansDrinkable bisphosphonatesGeneric drugOral bisphosphonatesOsteoporosisPersistence030212 general & internal medicineMedical prescriptionAdverse effectAgedRetrospective StudiesOral bisphosphonatesBone Density Conservation AgentsDiphosphonatesbusiness.industryOral bisphosphonatesSettore MED/34 - Medicina Fisica E RiabilitativaBisphosphonateMiddle Agedmedicine.diseaseDiscontinuationLogistic ModelsItalyCase-Control StudiesOsteoporosisFemaleGeriatrics and Gerontologybusiness030217 neurology & neurosurgeryOsteoporotic FracturesDrinkable bisphosphonates
researchProduct

A subgroup analysis of the ODYSSEY APPRISE study: Safety and efficacy of alirocumab in the Italian cohort.

2022

ODYSSEY APPRISE trial evaluated efficacy and safety of alirocumab in 994 patients with hypercholesterolemia and high CV risk in a real-life setting. The aim of the present report is to detail on the Italian cohort enrolled and treated in the trial.The methodology of the of the multinational, single-arm, Phase 3b open-label ODYSSEY APPRISE (Clinicaltrials.gov: NCT02476006) has been previously reported. 255 Italian patients were enrolled and treated according to the trial protocol. Overall mean exposure to alirocumab was 83.3 ± 27.7 weeks. At week 12, LDL-C decreased by 51.3 ± 23.1% and this reduction was overall maintained for the duration of the study. A similar reduction was observed in pa…

Settore MED/09 - Medicina InternaNutrition and DieteticsLDL-C.Endocrinology Diabetes and MetabolismAnticholesteremic AgentsMedicine (miscellaneous)alirocumabCholesterol LDLAntibodies Monoclonal HumanizedHyperlipoproteinemia Type IIheterozygous familial hypercholesterolemiaTreatment OutcomeItalyHumansheterozygous familial hypercholesterolemia; high cardiovascular risk; alirocumab; LDL-C; Italyhigh cardiovascular riskCardiology and Cardiovascular MedicineLDL-CNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct